MannKind | MNKD - Gross Profit On Sales


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

MannKind

MannKind reported $24.41M in Gross Profit on Sales for its fiscal quarter ending in March of 2023.


Gross Profit On Sales Change
BioCryst Pharmaceuticals BCRX:US USD 67.84M 9.21M
Eli Lilly LLY:US USD 5.33B 420.4M
Halozyme Therapeutics HALO:US USD 126.97M 12.4M
Immunogen IMGN:US USD 49.24M 8.25M
Insmed INSM:US USD 51.38M 5.15M
Karyopharm Therapeutics KPTI:US USD 37.35M 5.64M
MacroGenics MGNX:US USD 20.97M 50.34M
MannKind MNKD:US USD 24.41M 4.48M
Merck & Co MRK:US USD 11.14B 1.15B
Novavax NVAX:US USD 46.86M 128.77M
Novo Nordisk A Fs NVO:US DKK 45.18B 5.36B
Peregrine Pharmaceuticals PPHM:US USD 9.82M 5.68M
Pfizer PFE:US USD 13.26B 1.21B